Attovia grants CSO Petter Veiby 140,000 stock options

Attovia Therapeutics, Inc. reported that Chief Scientific Officer Petter Veiby received a grant of stock options covering 140,000 shares of common stock at an exercise price of $17.00 per share.

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. reported that Chief Scientific Officer Petter Veiby received a grant of stock options covering 140,000 shares of common stock at an exercise price of $17.00 per share. The options expire on August 3, 2036 and vest 25% on August 4, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service. Following this award, Veiby holds options on 140,000 shares directly.

Insider Trade Summary

Grant/Award: 140,000 shares

Grant/Award 1 txn

Insider Veiby Petter

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	140,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 140,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

Key Figures

Options Granted: 140,000 shares Exercise Price: $17.00 per share Expiration Date: August 3, 2036 +3 more

6 metrics

Options Granted 140,000 shares Stock Option (Right to Buy) grant to Chief Scientific Officer on 2026-08-04

Exercise Price $17.00 per share Conversion or exercise price of the stock options

Expiration Date August 3, 2036 Expiration of the stock option award

Initial Vesting Tranche 25% on August 4, 2027 First vesting date for the option grant

Remaining Vesting Period 36 months Remaining options vest in equal monthly installments after initial 25%

Post-Grant Holdings 140,000 options Total options held by Petter Veiby following the reported grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 17.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-08-03"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"25% of the options shall vest on August 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Attovia Therapeutics (ATTO) disclose about Petter Veiby’s new stock options?

Attovia Therapeutics disclosed that Chief Scientific Officer Petter Veiby received a grant of 140,000 stock options. These options relate to common stock, have a $17.00 exercise price, and expire on August 3, 2036, forming part of his equity-based compensation.

What is the exercise price of Petter Veiby’s new Attovia (ATTO) stock options?

The exercise price of Petter Veiby’s new options is $17.00 per share. This means he can purchase up to 140,000 shares of Attovia common stock at $17.00, subject to the vesting schedule and his continued service to the company.

How do Petter Veiby’s Attovia (ATTO) stock options vest over time?

Veiby’s options vest 25% on August 4, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months. Vesting is expressly conditioned on his continued service to Attovia through the applicable vesting dates.

When do Petter Veiby’s newly granted Attovia (ATTO) options expire?

The newly granted options expire on August 3, 2036. After this expiration date, Veiby will no longer be able to exercise the 140,000 options, even if they have vested, so long-term value depends on exercising before that date.

How many Attovia (ATTO) options does Petter Veiby hold after this grant?

After this grant, Petter Veiby holds options covering 140,000 shares of Attovia common stock directly. This entire amount relates to the newly awarded stock option grant reported in the filing, reflecting his current option position from this award.

Is Petter Veiby’s Attovia (ATTO) option grant a market purchase or a compensation award?

The reported transaction is a grant/award acquisition of stock options, not a market purchase. It carries a transaction code for a grant, award, or other acquisition and an exercise price of $17.00, consistent with equity compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/08/2026 - 02:11 PM Accepted by SEC EDGAR 08/06/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Veiby Petter

(Last) (First) (Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	08/04/2026		A		140,000		(1)	08/03/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

	/s/ Steven Chan, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)